Objective:

To assess the effects of endocrine therapy on vaginal microbiome diversity and dominant taxa, explore dose–response links between microbiome shifts and GSM severity, and compare impacts of OFS + AI versus OFS + TAM on vaginal microecology.

Approach:

Key Findings:

• Endocrine therapy often induces GSM symptoms due to hypoestrogenism.
• Approximately 70% of patients develop GSM symptoms post-treatment.
• Vaginal microbiome changes, particularly Lactobacillus depletion, are linked to GSM severity.

Interpretation:

Limitations:

• Limited longitudinal data on vaginal microbiome changes in breast cancer survivors.
• Previous studies have small sample sizes and cross-sectional designs.

Conclusion:

This protocol aims to enhance understanding of vaginal microecology in breast cancer patients undergoing endocrine therapy.

Sources:

• Clinical Trial Registration
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.